Publications


The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. Agnieszka Pałucha-Poniewiera, Karolina Podkowa, Tomasz Lenda, Andrzej Pilc
Progress in neuro-psychopharmacology & biological psychiatry, S0278-5846(17)30220-8 10.1016/j.pnpbp.2017.06.022
PMID:28647535

Sunday, 25 June 2017
Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats. Zofia Rogóż, Katarzyna Kamińska, Patrycja Pańczyszyn-Trzewik, Magdalena Sowa-Kućma
Pharmacological reports : PR, S1734-1140(16)30398-X 10.1016/j.pharep.2017.02.022
PMID:28624596

Sunday, 18 June 2017
Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Rafał R Jaeschke, Katherine Sendek, Krzysztof Styczeń, Wojciech Datka, Magdalena Koperny
Pharmacological reports : PR, S1734-1140(16)30361-9 10.1016/j.pharep.2017.01.030
PMID:28499187

Friday, 12 May 2017
Neuropeptide Y Y2 and Y5 receptors as promising targets for neuroprotection in primary neurons exposed to oxygen-glucose deprivation and in transient focal cerebral ischemia in rats. Helena Domin, Łukasz Przykaza, Danuta Jantas, Ewa Kozniewska, Paweł M Boguszewski, Maria Śmiałowska
Neuroscience, S0306-4522(16)30740-0 10.1016/j.neuroscience.2016.12.040
PMID:28057538

Friday, 6 January 2017
Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence. Helena Domin, Bernadeta Szewczyk, Bartłomiej Pochwat, Monika Woźniak, Maria Śmiałowska
Psychopharmacology,
PMID:27975125

Thursday, 15 December 2016
SERS characterization of neuropeptide Y and its C-terminal fragments deposited onto colloidal gold nanoparticle surface. Helena Domin, Natalia Piergies, Dominika Święch, Ewa Pięta, Edyta Proniewicz
Colloids and surfaces. B, Biointerfaces, S0927-7765(16)30704-4 10.1016/j.colsurfb.2016.10.001
PMID:27736725

Thursday, 13 October 2016
Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Karolina Podkowa, Adrian Podkowa, Kinga Sałat, Tomasz Lenda, Andrzej Pilc, Agnieszka Pałucha-Poniewiera
Neuropharmacology, S0028-3908(16)30367-7 10.1016/j.neuropharm.2016.08.031
PMID:27569995

Monday, 29 August 2016
Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022. Monika Woźniak, Krystyna Gołembiowska, Karolina Noworyta-Sokołowska, Francine Acher, Paulina Cieślik, Magdalena Kusek, Krzysztof Tokarski, Andrzej Pilc, Joanna M Wierońska
Neuropharmacology, S0028-3908(16)30278-7 10.1016/j.neuropharm.2016.06.025
PMID:27465045

Tuesday, 9 August 2016
Glutamate-Based Drug Discovery for Novel Antidepressants. Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Expert opinion on drug discovery, 10.1080/17460441.2016.1213234
PMID:27409299

Wednesday, 3 August 2016
Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Karolina Podkowa, Bartłomiej Pochwat, Piotr Brański, Andrzej Pilc, Agnieszka Pałucha-Poniewiera
Psychopharmacology, 10.1007/s00213-016-4325-7
PMID:27286960

Saturday, 11 June 2016